GlaxoSmithKline reportedly threatened diabetes expert over Avandia warnings

Email this article to a friend

Printable Version

Articles Related to This Article: • FDA refuses to pull dangerous diabetes drug Avandia, even knowing it will kill thousands • Avandia Study Shows 60 Percent Increase in Heart Failure Risk Among Diabetics who Take the Drug • FDA Collaboration with Big Pharma Raises Eyebrows Support NaturalNews advertisers - Advertise with NaturalNews Help support NaturalNews with health books and educational programs from Truth Publishing: • Swine Flu Advanced Preparedness • 8 Weeks to Vibrant Health • Raw In Ten Minutes (recipes) • How to Halt Diabetes in 25 Days ... and much more.

(NaturalNews) A diabetes expert has claimed that pharmaceutical company GlaxoSmithKline threatened him with legal action after he raised concerns about the safety of the company's anti-diabetes drug rosiglitazone, marketed as Avandia.

In a written testimony to a congressional subcommittee, John Buse of the University of North Carolina said that he received phone calls from company executives in 1999, just after Avandia's release, warning him that his comments about the drug "were scurrilous enough to attempt to hold me liable for a loss in market capitalization." Buse later signed a statement, drafted by GlaxoSmithKline, attempting to alleviate the concerns that his comments had raised with stockholders.

GlaxoSmithKline's CEO J.P. Garnier has denied that the company made any threats, saying instead that Buse made a "correction" to his prior comments.

In March 2000, Buse -- who is expected to become the next president of the American Diabetes Association -- warned the FDA that Avandia might increase users' risk of heart attacks. He also publicly criticized the company's "blatant selective manipulation of data," which he said functioned to make the drug appear more effective and less dangerous.

Buse's recent comments were directed to the House Committee on Oversight and Government Reform, which is investigating the FDA's role in approving Avandia. The committee convened a hearing on the issue after the New England Journal of Medicine announced that it would be publishing a study linking Avandia use to increased cardiovascular problems. The study, published on June 14, found that the drug led to a 43 percent higher risk of heart attack and a 64 percent higher risk of heart death.

As a result, Congress is investigating why the early warnings given by Buse and the World Health Organization were not heeded in the FDA approval process.

The FDA's process for approving new drugs has come under increasing fire recently, spurred on by scandals such as the discovery that Merck's popular anti-inflammatory Vioxx led to increased risk of heart attack and stroke.

Share

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • FDA refuses to pull dangerous diabetes drug Avandia, even knowing it will kill thousands • Avandia Study Shows 60 Percent Increase in Heart Failure Risk Among Diabetics who Take the Drug • FDA Collaboration with Big Pharma Raises Eyebrows	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/022290_Avandia_GlaxoSmithKline_diabetes.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/022290_Avandia_GlaxoSmithKline_diabetes.html">GlaxoSmithKline reportedly threatened diabetes expert over Avandia warnings</a>